Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published June 1991 | public
Journal Article

Recombinant Cholinergic Differentiation Factor (Leukemia Inhibitory Factor) Regulates Sympathetic Neuron Phenotype by Alterations in the Size and Amounts of Neuropeptide mRNAs

Abstract

The cholinergic differentiation factor (CDF) in heart cells is identical to leukemia inhibitory factor (LIF). Recombinant CDF/LIF was shown to alter dramatically neurotransmitter production as well as the levels of several neuropeptides in cultured rat sympathetic neurons. Here it is shown that these changes are likely to be caused by alterations in the mRNA for these proteins and peptides. Growth in 1 nM recombinant CDF/LIF induces mRNA for acetyl CoA: choline-O-acetyltransferase [EC 2.3.1.6; choline acetyltransferase (ChAT)], somatostatin (SOM), substance P, and vasoactive intestinal polypeptide while lowering mRNA levels of tyrosine hydroxylase (EC 1.14.16.2) and neuropeptide Y (NPY). In addition, the sizes of the mRNAs for ChAT, SOM, and NPY are larger after recombinant CDF/LIF treatment.

Additional Information

© 1991 International Society for Neurochemistry. Received February 28, 1991; accepted March 5, 1991. We thank Dr. D. Metcalf for the recombinant CDF/LIF, Drs. K. Fukada and T. Yamamori for advice, and D. McDowell for th preparatiojn of tissue media and collagen. We are also grateful to the researchers who generously provided us with rat cDNA proves: Dr. H. Okamoto (VIP), Dr. S. Sabol (NPY), Dr. D. Chikaraishi (TH), and Dr. T. Deguchi (ChAT). This work was supported by grants from the National Institute of Neurological Disorders and Stroke (Javits Neuroscience Investigator Award) and the McKnight Foundation Neuroscience Research Project Award (to P. H. Patterson) and by the Ministry of Education, Science and Culture of Japan (to H. Nawa).

Additional details

Created:
August 22, 2023
Modified:
October 25, 2023